California Peptide Research, Inc. introduces HFIP treated beta amyloids
April 1, 2010 — California Peptide Research, Inc. (CPRI) announces the introduction of HFIP (hexafluoroisopropanol) treated beta amyloids to its existing catalog of neuropeptides. The new HFIP treated beta amyloids will be offered in the 1-40 and 1-42 variants in 1.0 mg and 0.5 mg quantities.
HFIP treated beta amyloids have been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promote α-helical secondary structure
“This marks a continuation of CPRI's focus and commitment on high quality neurology peptides where we have been an industry leader for 17 years,” said Fabio Simi, president of CPRI. The company also continues to innovate in other therapeutic categories including cardiovascular, central nervous system, gastrointestinal, metabolic/diabetes and obesity.
About California Peptide Research, Inc.
California Peptide Research, Inc. (CPRI) provides high purity custom and catalog peptides. CPRI is a global manufacturing partner and supplier of reagents to leading life science organizations, government agencies and research professionals that require a wide variety of capabilities and service offerings. CPRI is located in Napa, California and was founded in 1993 and can be reached by calling (800) PEPTIDE.